At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01952 EVEREST MED
Not Yet Opened 09-02 16:08:07
32.220
-1.000
-3.01%
High35.560Low32.180Vol10.61M
Open34.800D1 Closing33.220Amplitude10.17%
Mkt Cap11.41BTradable Cap11.41BTotal Shares354.00M
T/O355.32MT/O Rate3.00%Tradable Shares354.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜EVEREST MED Rises 6.56% in Regular Trading, Rebounding After Recent Profit-Taking as mRNA Biotech Sector Recovers
Market Focus  ·  09-02 09:35
Movement Alert｜EVEREST MED Rises 6.56% in Regular Trading, Rebounding After Recent Profit-Taking as mRNA Biotech Sector Recovers
Movement Alert｜EVEREST MED Falls 5.19% in Regular Trading, mRNA Concept Pullback and Biotech Sector Weakness Weigh on Shares
Market Focus  ·  08-31 10:09
Movement Alert｜EVEREST MED Falls 5.19% in Regular Trading, mRNA Concept Pullback and Biotech Sector Weakness Weigh on Shares
Movement Alert｜EVEREST MED Falls 5.2% in Regular Trading, mRNA Concept Sentiment Cooling and Sector Weakness Trigger Pullback
Market Focus  ·  08-28
Movement Alert｜EVEREST MED Falls 5.2% in Regular Trading, mRNA Concept Sentiment Cooling and Sector Weakness Trigger Pullback
Movement Alert｜EVEREST MED Rises 5.16% in Regular Trading, mRNA Momentum and Strong Earnings Continue to Fuel Rally
Market Focus  ·  08-26
Movement Alert｜EVEREST MED Rises 5.16% in Regular Trading, mRNA Momentum and Strong Earnings Continue to Fuel Rally
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals
Stock News  ·  08-25
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals
Everest Med Surges Over 17% in Afternoon Trade as Core Drug Nefecon Drives Strong Revenue Growth
Deep News  ·  08-25
Everest Med Surges Over 17% in Afternoon Trade as Core Drug Nefecon Drives Strong Revenue Growth
Midday Market Snapshot: Hang Seng Index Slips 0.25% in Morning Session, Mainland Property Stocks Rally Broadly
Stock News  ·  08-25
Midday Market Snapshot: Hang Seng Index Slips 0.25% in Morning Session, Mainland Property Stocks Rally Broadly
Movement Alert｜EVEREST MED Rises 5.14% in Regular Trading, mRNA Catalyst Sustains as Broker Reaffirms Buy Rating
Market Focus  ·  08-25
Movement Alert｜EVEREST MED Rises 5.14% in Regular Trading, mRNA Catalyst Sustains as Broker Reaffirms Buy Rating
mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence
Deep News  ·  08-24
mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence
Movement Alert｜EVEREST MED Rises 5.28% in Regular Trading, Technical Rebound as mRNA Catalyst Lingers and Broker Maintains Buy Rating
Market Focus  ·  08-24
Movement Alert｜EVEREST MED Rises 5.28% in Regular Trading, Technical Rebound as mRNA Catalyst Lingers and Broker Maintains Buy Rating
Movement Alert｜EVEREST MED Intraday Decline 6.77%, Profit-Taking After Previous Session mRNA-Fueled 41% Surge
Market Focus  ·  08-21
Movement Alert｜EVEREST MED Intraday Decline 6.77%, Profit-Taking After Previous Session mRNA-Fueled 41% Surge
Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Simply Wall St.  ·  08-21
Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Medical Stocks Surge on Breakthrough News: Everest Med Jumps Over 70% Intraday, Wuxi Apptec Hits New High, and ETFs See Explosive Volume
Deep News  ·  08-20
Medical Stocks Surge on Breakthrough News: Everest Med Jumps Over 70% Intraday, Wuxi Apptec Hits New High, and ETFs See Explosive Volume
HK Movers | Pharma Stocks Surge With 3D Medicines up 68%, CanSino Biologics up 52%
Tiger Newspress  ·  08-20
HK Movers | Pharma Stocks Surge With 3D Medicines up 68%, CanSino Biologics up 52%
EVEREST MED Surges Over 89% at Market Open on Strong First-Half Revenue of 1.148 Billion Yuan, Up 157% Year-on-Year
Deep News  ·  08-20
EVEREST MED Surges Over 89% at Market Open on Strong First-Half Revenue of 1.148 Billion Yuan, Up 157% Year-on-Year
Movement Alert｜EVEREST MED Rises 47.06% in Regular Trading, mRNA Vaccine Breakthrough and Strong Interim Results Drive Dual Catalyst Rally
Market Focus  ·  08-20
Movement Alert｜EVEREST MED Rises 47.06% in Regular Trading, mRNA Vaccine Breakthrough and Strong Interim Results Drive Dual Catalyst Rally
Everest Medicines Surges 15% as Moderna's Cancer Vaccine Breakthrough Revitalizes mRNA Sector
Stock News  ·  08-20
Everest Medicines Surges 15% as Moderna's Cancer Vaccine Breakthrough Revitalizes mRNA Sector
EVEREST MED Posts Strong Interim Results with Revenue Soaring 157% as Nefecon Commercial Launch and Real-World Data Gain Momentum
Stock News  ·  08-19
EVEREST MED Posts Strong Interim Results with Revenue Soaring 157% as Nefecon Commercial Launch and Real-World Data Gain Momentum
Everest Medicines H1 Revenue RMB 701.7 Million
THOMSON REUTERS  ·  08-19
Everest Medicines H1 Revenue RMB 701.7 Million
Everest Medicines FY26 H1 Net Loss Narrows to RMB 5.9 Million; Revenue More than Doubles to RMB 1.15 Billion
Reuters  ·  08-19
Everest Medicines FY26 H1 Net Loss Narrows to RMB 5.9 Million; Revenue More than Doubles to RMB 1.15 Billion
No data available

Introduction

Company Name.
EVEREST MED
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.
Issue price:
--